Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 May;17(5):558-560.
doi: 10.1038/s41423-019-0276-3. Epub 2019 Sep 12.

TOX: a rediscovered master molecular actor to enhance immuno-oncology interventions

Alain A Vertès  1
Affiliations
Comment

TOX: a rediscovered master molecular actor to enhance immuno-oncology interventions

Alain A Vertès. Cell Mol Immunol. 2020 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Balancing tissue integrity and T-cell action in chronic inflammation: the physiological role of TOX as a master regulator of T-cell exhaustion. By inducing T-cell exhaustion in conditions of chronic inflammation, TOX limits tissue damage that would result from a persistent acute inflammation process and prevents activation-induced cell death, thereby permitting extended persistence of CD8+ T cells. This extended persistence enables the maintenance of some level of immune control during chronic infection or cancer, akin to a “physiological plan B”, when the acute phase fails to clear the infectious agent. TOX is an exciting new target in immuno-oncology for combination therapy in solid tumors
See this image and copyright information in PMC

Comment on

References

    1. Eshhar Z, Waks T, Gross G. The emergence of T-bodies/CAR T cells. Cancer J. 2014;20:123–126. doi: 10.1097/PPO.0000000000000027. - DOI - PubMed
    1. Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423–431. doi: 10.1038/nature22395. - DOI - PMC - PubMed
    1. June CH, Sadelain M. Chimeric antigen receptor therapy. New Engl. J. Med. 2018;379:64–73. doi: 10.1056/NEJMra1706169. - DOI - PMC - PubMed
    1. Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer cell. 2018;33:547–562. doi: 10.1016/j.ccell.2018.03.012. - DOI - PMC - PubMed
    1. Siddiqui I, et al. Intratumoral Tcf1+PD-1+CD8+T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195–211. doi: 10.1016/j.immuni.2018.12.021. - DOI - PubMed